Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of siRNA payloads to target KRAS-mutant cancer.

Cancer discovery - 1 Oct 2014

Yuan Tina L, Fellmann Christof, Lee Chih-Shia, Ritchie Cayde D, Thapar Vishal, Lee Liam C, Hsu Dennis J, Grace Danielle, Carver Joseph O, Zuber Johannes, Luo Ji, McCormick Frank, Lowe Scott W

Abstract excerpt

UNLABELLED: RNAi is a powerful tool for target identification and can lead to novel therapies for pharmacologically intractable targets such as KRAS. RNAi therapy must combine potent siRNA payloads with reliable in vivo delivery for efficient target inhibition. We used a functional "Sensor" assay to establish a library of potent siRNAs against RAS pathway genes and to show that they efficiently suppress their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Delivery Systems
Share to Gene Knockdown Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Library

Share to Gene Transfer Techniques

Share to Nanoparticles

Share to Phosphatidylinositol 3-Kinases

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 25100204
DOI: 10.1158/2159-8290.CD-13-0900
PMCID: PMC4184972

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of siRNA payloads to target KRAS-mutant cancer.PMID 25100204Read ↗

Advancements in gene therapies targeting mutant KRAS in cancers.Semantic proximity Read ↗

EGFR blockade confers sensitivity to pan-RAS inhibitors in KRAS-mutated cancers.Semantic proximity Read ↗

Protocols to evaluate mutant specificity of an oncogene-targeting siRNA using orthogonal in vitro and in vivo approaches.Semantic proximity Read ↗

Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.Semantic proximity Read ↗

Mutant KRAS is a druggable target for pancreatic cancer.Semantic proximity Read ↗

Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.Semantic proximity Read ↗

KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex.Semantic proximity Read ↗

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS.Semantic proximity Read ↗

Synthetic gene circuits that selectively target RAS-driven cancersSemantic proximity Read ↗

Synthetic gene circuits that selectively target RAS-driven cancers.Semantic proximity Read ↗

Combination of KRAS gene silencing and PI3K inhibition for ovarian cancer treatment.Semantic proximity Read ↗

Statin-dye conjugates for selective targeting of <i>KRAS</i> mutant cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.